Quarterly ResultAug 5, 2026, 08:05 AM
ImageneBio Q2 Net Loss $10.2M; $136.2M Cash Funds into Q1 2028
AI Summary
ImageneBio reported a Q2 2026 net loss of $10.2 million, an improvement from $10.7 million in Q2 2025, with a net loss per share of $0.63. The company ended the quarter with $136.2 million in cash, cash equivalents, and marketable securities, providing anticipated funding into Q1 2028. Clinical development for olevaprubart (IMG-007) is progressing, with the Phase 2b ADAPTIVE trial for atopic dermatitis on track for Q4 2027 topline data, and a Phase 2 trial for alopecia areata planned for 2026. Imagene also strengthened its leadership team with new CFO and General Counsel appointments.
Key Highlights
- Q2 2026 net loss was $10.2 million, down from $10.7 million in Q2 2025.
- Net loss per share was $0.63 for Q2 2026, compared to $4.46 in Q2 2025.
- Cash, cash equivalents, and marketable securities totaled $136.2 million as of June 30, 2026.
- Company anticipates funding planned operations into the first quarter of 2028.
- R&D expenses increased to $6.7 million for Q2 2026 from $5.7 million in Q2 2025.
- G&A expenses rose to $5.1 million for Q2 2026 from $1.7 million in Q2 2025.
- Topline data for the Phase 2b ADAPTIVE trial is anticipated in Q4 2027.
- Yanina Grant-Huerta was appointed Chief Financial Officer in July 2026.
Price Impact
More from IMA